By using a transposon-mediated oncogene-induced HCC model, the Lujambio laboratory found that the activation of β-catenin signaling in HCC blocked CCL5 secretion, resulting in reduced dendritic cell recruitment, decreased T cell activity, and resistance to anti-PD-1 treatment [70]. The gene discussed is CCL5; the disease is hepatocellular carcinoma.